Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

UPDATE: Valeant Releases Details On Hospital Discount Plan For Heart Drugs

XTALKS VITALS NEWS

Hospital Pharmacy

According to a statement released by Valeant, all hospitals will be eligible to receive a 10 percent rebate on the heart drugs, with some high volume centers benefitted from as much as a 40 percent discount.

Share this!

May 18, 2016 | by Sarah Massey, M.Sc.

Amid criticism over Valeant’s failure to deliver on promised hospital discounts for two of their heart drugs, the company has released the details of its rebate program for Isuprel and Nitropress. While these volume-based discounts were announced earlier this year, the company has faced considerable criticism from Congress over drug pricing and patient access.

According to a statement released by Valeant, all hospitals will be eligible to receive a 10 percent rebate on the heart drugs, with some high volume centers benefitted from as much as a 40 percent discount. Valeant’s new Patient Access and Pricing committee has also vowed to neither increase the price of the drugs, nor decrease the discounts available.



While this is welcome news to hospital pharmacy administrators, Valeant has already raised the price of Isuprel and Nitropress by 720 percent and 310 percent, respectively, since acquiring the drugs in early 2015. Representatives from Valeant appeared in front of the Senate Aging Committee on April 27, where they were confronted by senators regarding the lack of hospitals that had received the discounts.

With the release of the statement earlier this week, it looks like Valeant is making strides to ensure hospitals get the drugs at reduced prices. According to the company, the discounts will likely be offered to group purchasing organizations as opposed to directly dealing with individual hospitals.

“Under this new program, the discounts we previously implemented for Nitropress and Isuprel will be simplified and more accessible,” said Joseph Papa, CEO of Valeant. “I understand the concerns our partners in the health care community have had about the pricing of these drugs, and we want to ensure hospitals and patients can get the drugs they need.

“I also want to thank the Senate Committee on Aging and the House Committee on Oversight and Government Reform for the attention they have brought to this issue, and specifically to gaps they identified in the previous program,” said Papa. “We are committed to getting this right.”


Keywords: Drug Pricing, Heart Drug, Hospital Pharmacy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Kite Pharma Secures FDA Approval for CAR-T Immunotherapy

October 20, 2017 - Kite Pharma’s Yescarta (axicabtagene ciloleucel) has become the second CAR-T immunotherapy to be approved in the US, with an indication in treating adult patients with relapsed or refractory large B-cell lymphoma.

Featured In: Biotech News


Fallopian Tubes Found to be Site of Origin for Most Ovarian Cancers

October 20, 2017 - This year, over 22,000 women will be diagnosed with ovarian cancer but a new study conducted by researchers at Perlmutter Cancer Center at NYU Langone Health suggests that most of these malignancies begin in another part of the reproductive system: the fallopian tubes.

Featured In: Life Science News


Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Brexit – Separating Fact from Fiction


Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond


Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms


Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution


Copyright © 2016-2017 Honeycomb Worldwide Inc.